Overview

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well TAS-102 and oxaliplatin work in treating patients with stage IV colon cancer. Drugs used in chemotherapy, such as TAS-102 and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Phase:
Phase 2
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborator:
National Cancer Institute (NCI)
Treatments:
Oxaliplatin
Trifluridine